ClinicalTrials.gg
RecruitingNCT07111000Updated May 11, 2026

Testing the Epley Maneuver for Treating Dizziness in the Emergency Department

An interventional study of Epley Maneuver and Sham maneuver in Benign Paroxysmal Positional Vertigo (BPPV), sponsored by American University of Beirut Medical Center. Recruiting at 1 site in Lebanon. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by American University of Beirut Medical Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Aug 2024, registered Aug 2025).
  • Started Aug 2024; still recruiting 2 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this randomized controlled trial is to evaluate the efficacy of the Epley maneuver versus a sham maneuver in treating patients presenting to the emergency department (ED) with BPPV. The main questions that the study aims to answer are:

  • What is the mean difference in Dizziness Handicap Inventory (DHI) scores between patients receiving the Epley maneuver and those receiving the sham maneuver 3 days after enrollment?
  • What is the immediate response (using a 0-10-point Likert scale) of patients in each arm of the study?
  • What is the proportion of patients who, despite agreeing to participate, were unable to complete the full Epley maneuver due to symptom severity?

Researchers will compare the Epley maneuver arm to the sham maneuver arm to see if the Epley maneuver is more effective in reducing BPPV symptoms.

Participants will:

  • Undergo either the Epley maneuver or a sham maneuver.
  • Complete the Dizziness Handicap Inventory (DHI) questionnaire at baseline and 3 days post-discharge.
  • Patients with insufficient improvement in the sham maneuver group will receive a rescue Epley maneuver.
  • Have their vertigo severity assessed using a 0-10 point Likert scale at baseline, immediately and post-maneuver.
02

Conditions studied

  • Benign Paroxysmal Positional Vertigo (BPPV)

Keywords

  • Epley
  • vertigo
  • bening paroxysmal positional vertigo
03

In context

Benign Paroxysmal Positional Vertigo

75 studies on the registry are indexed under Benign Paroxysmal Positional Vertigo; 15 are open to participants now.

This study's planned enrollment of 118 is above the median of 78 across 62 interventional studies indexed under Benign Paroxysmal Positional Vertigo.

Browse Benign Paroxysmal Positional Vertigo studies →

Lead sponsor

American University of Beirut Medical Center is the lead sponsor of 158 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  • Age: above 18 years old
  • Patients presenting to the ED with symptoms of BPPV (single or recurrent episodes of vertigo lasting up to 2 minutes) and a positive DHT (episode of vertigo associated with torsional upbeating nystagmus) indicating a posterior semicircular canal BPPV.
  • Patients who are able to understand and provide a signed to participate in the study Exclusion Criteria
  • Severe cervical diseases (e.g., soft tissue disorders, cervical spondylosis, prolapsed intervertebral disks and severe rheumatoid arthritis with cervical instability …)
  • Unstable cardiovascular diseases (e.g., hemodynamically unstable, decompensated heart failure, acute myocardial infarction, decompensated valvular diseases, severe arrhythmias …)
  • Suspected vertebrobasilar diseases (e.g., cerebellar signs, vision changes, numbness or tingling in the extremities, slurred speech, changes in mental status, confusion …)
  • History of high-grade carotid stenosis
  • Recent (\<24 hours) intake of aminoglycosides, chemotherapeutic agents, cyclophosphamide, loop diuretics, or quinines
  • Patients with peripheral causes of vertigo other than BPPV (such as Meniere's disease or vestibular neuritis)
  • Patients with central causes of vertigo (vestibular migraine, Arnold Chiari malformation, history of CNS tumor(s), multiple sclerosis)
  • Patients with focal deficits on neurological exam
  • Patients with an episode of vertigo lasting more than 2 minutes
  • Patients with a negative DHT
  • Patients with pure horizontal or vertical nystagmus
  • Patients with lateral and anterior semicircular canals BPPV
  • Participants refusing to undergo Epley maneuver
  • Pregnancy beyond the 24th week of gestation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
118 participants (estimated)

Study arms

  • Experimental
    Epley Maneuver

    The patient's head is turned 45 degrees towards the side that caused the most nystagmus or reproduced their initial symptoms. The patient is then laid down with their head hanging over the edge of the bed. After that, the head will be rotated 90 degrees in the opposite direction, with the head remaining in a dependent position. The patient is then asked to roll onto their side with their head facing downward. They are then brought back to a sitting position and the head is moved forward 45 degrees. Each position is held until the vertigo and/or nystagmus subsides or for at least 30 seconds

    Procedure: Epley Maneuver

  • Sham comparator
    Sham Maneuver

    This maneuver will involve coordinated movements of the hands and legs, while excluding any head movement. Patients will be at first in a sitting position with both feet on the ground and both hands placed on the thighs and then they will be asked to lift both hands off the thighs, keeping the arms extended. They will then be asked to return to their initial upright sitting position. Patients will then raise their right foot off the ground while keeping the left one planted on the ground. It will be an alternating movement between lifting the right and left feet while maintaining a smooth and well-controlled rhythm for 90 seconds.

    Procedure: Sham maneuver

Interventions

  • ProcedureEpley Maneuver

    The patient's head is turned 45 degrees towards the side that caused the most nystagmus or reproduced their initial symptoms. The patient is then laid down with their head hanging over the edge of the bed. After that, the head will be rotated 90 degrees in the opposite direction, with the head remaining in a dependent position. The patient is then asked to roll onto their side with their head facing downward. They are then brought back to a sitting position and the head is moved forward 45 degrees. Each position is held until the vertigo and/or nystagmus subsides or for at least 30 seconds

  • ProcedureSham maneuver

    This control maneuver will involve coordinated movements of the hands and legs, while excluding any head movement. Patients will be at first in a sitting position with both feet on the ground and both hands placed on the thighs and then they will be asked to lift both hands off the thighs, keeping the arms extended. They will then be asked to return to their initial upright sitting position. Patients will then raise their right foot off the ground while keeping the left one planted on the ground. It will be an alternating movement between lifting the right and left feet while maintaining a smooth and well- controlled rhythm for 90 seconds.

06

What researchers measure

Primary outcomes

  1. Efficacy of Epley

    The study will compare the average Dizziness Handicap Inventory score change from baseline to day 3 between the Epley maneuver group and the sham maneuver group. The DHI is a 25-item self-administered questionnaire designed to assess the effects of dizziness on various aspects of life, including functional, emotional, and physical domains. Scores range from 0, indicating no disability, to 100, representing severe disability. This scale enables patients to indicate how much dizziness interferes with their daily activities. A higher score reflects a greater perceived handicap caused by dizziness.

    Time frame: 3 days

Secondary outcomes

  1. Immediate response of patients

    The severity of vertigo will be evaluated using both a 0 to 10-point Likert scale before and after applying the Epley/Sham maneuver.

    Time frame: 15-30 minutes after intervention

  2. Rate of bounce-back to the ED

    Calculate the proportion of patients in each arm of the study who return to the ED.

    Time frame: 3 days

  3. Proportion of patients unable to undergo the full Epley maneuver

    The percentage of patients who agreed to participate but could not complete the Epley maneuver due to the severity of their symptoms.

    Time frame: 15 minutes

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jul 2026, 23 months after the start.

Of 38 non-industry interventional studies with no phase under Benign Paroxysmal Positional Vertigo, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 26. This study's planned 23 months is above that.

Counting every sponsor, half of 39 studies reached it within 16 months; a quarter within 8 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Aug 8, 2025
StartActual
Aug 1, 2024
Primary completionEst.
Jul 22, 2026
CompletionEst.
Aug 22, 2026
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07111000
Responsible party
Eveline Hitti (Professor of Clinical Specialty, American University of Beirut Medical Center) — Principal investigator
First posted
Aug 8, 2025
Start date
Aug 1, 2024
Primary completion
Jul 22, 2026 (estimated)
Completion
Aug 22, 2026 (estimated)
Last update
May 11, 2026

Study contacts

Eveline Hitti, MD
Contact
eh16@aub.edu.lb
00961-1-350000 ext. 6616

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion